Research Paper Volume 15, Issue 21 pp 12369—12387
CCL19: a novel prognostic chemokine modulates the tumor immune microenvironment and outcomes of cancers
Figure 1. Association of CCL19 expression with improved survival in breast and ovarian cancers. (A, B) In BRCA and OV, the expression of CCL19 is associated with cancer suppression, manifested in better OS. Red represents a positive correlation with carcinogenesis, while blue represents cancer inhibition. (C) Kaplan-Meier survival analysis suggested the antitumor effect of CCL19 in patients with BRCA and OV (first row: PFS, second row: OS). (D) Univariate and multivariate Cox regression analysis indicated CCL19 expression as an independent prognostic biomarker for OS in patients with BRCA. (E) Robust nomogram was constructed to predict survival for patients with BRCA.